Title:
PHARMACEUTICAL METHODS, DOSING REGIMES AND DOSAGE FORMS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
Document Type and Number:
WIPO Patent Application WO2005065069
Kind Code:
A3
Abstract:
In general, the invention relates to a pharmaceutical dose having R-flurbiprofen as the active ingredient that upon oral administration of a single dose to a fasting subject provides a Cmax of about 30-95 µg per mL. When the dose is administered to an individual having mild-to-moderate Alzheimer's disease (or desiring protection against Alzheimer's disease) twice daily for at least 4 months according to the described guidelines, an improvement or lessening in decline of cognitive function as characterized by cognition tests is observed in the patient. The composition of the invention is formulated with one or more pharmaceutically acceptable excipients, salts or carriers.
More Like This:
| JP2023536371 | Ibuprofen ester derivative and its emulsion preparation |
| JP2007137896 | IBUPROFEN-CONTAINING PHARMACEUTICAL PREPARATION |
| WO/2019/131759 | INTESTINAL BARRIER FUNCTION-ENHANCING COMPOSITION |
Inventors:
HOBDEN ADRIAN (US)
ZAVITZ KENTON (US)
MATHER GARY (US)
HENDRIX SUZANNE (US)
ZAVITZ KENTON (US)
MATHER GARY (US)
HENDRIX SUZANNE (US)
Application Number:
PCT/US2004/022339
Publication Date:
September 22, 2005
Filing Date:
July 12, 2004
Export Citation:
Assignee:
MYRIAD GENETICS INC (US)
HOBDEN ADRIAN (US)
ZAVITZ KENTON (US)
MATHER GARY (US)
HENDRIX SUZANNE (US)
HOBDEN ADRIAN (US)
ZAVITZ KENTON (US)
MATHER GARY (US)
HENDRIX SUZANNE (US)
International Classes:
A61K31/192; A61K9/20; A61K9/28; (IPC1-7): A61K9/48; A61K31/19
Foreign References:
| US6160018A | 2000-12-12 | |||
| US20010012849A1 | 2001-08-09 | |||
| US5206029A | 1993-04-27 | |||
| US5200198A | 1993-04-06 |
Other References:
See also references of EP 1651195A4
Download PDF: